Clinical Trial Update: LAS41008 in Moderate to Severe Chronic Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 study LAS41008 for moderate to severe plaque psoriasis has completed, as reported in the clinical trial update from Almirall.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• LAS41008

Snippet

Sponsor: Almirall, S.A. | Conditions: Plaque Psoriasis | Phase 3 | Status: COMPLETED